Utility of Inflammatory Markers in Predicting Hepatocellular Carcinoma Survival after Liver Transplantation

Table 1

Patient characteristics and correlation with inflammatory markers.

	NLR			dNLR			LMR			PLR
	<5	≥5	P	<3	≥3	P	<3.45	≥3.45	P	<150	≥150	P
N	122	38		135	25		98	62		133	27
Male	78.7%	76.3%	0.76	78.5%	76%	0.78	78.6%	77.4%	0.86	78.9%	74.1%	0.58
Age (Year) mean ± SD	57±8	58±7	0.76	57±8	57±8	0.92	58±7	57±8	0.54	57±8	58±7	0.80
White race	74.6%	84.2%	0.22	75.6%	84%	0.36	78.6%	74.2%	0.52	76.7%	77.8%	0.90
HCV etiology	75.4%	71.1%	0.59	74.1%	76%	0.84	70.4%	80.6%	0.15	74.4%	74.1%	0.97
MELD, mean ± SD	12±7	17±10	0.004	12±7	18±11	0.02	16±8	9±6	0.003	13±8	12±8	0.57

dNLR, derived neutrophil lymphocyte ratio; HCV, hepatitis C virus; LMR, lymphocyte monocyte ratio; MELD, Model for End Stage Liver Disease; NLR, neutrophil lymphocyte ratio; PLR, platelet lymphocyte ratio.